A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

NCT02981108 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

364

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonsmall Cell Lung Cancer

Interventions

DRUG: HS-10296

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.